Crossmark

Analysing the landscape for prescription to non-prescription reclassification (switch) in Germany: an interview study of committee members and stakeholders

Crossref DOI link: https://doi.org/10.1186/s12913-019-4219-6

Published Online: 2019-06-20

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gauld, Natalie J. https://orcid.org/0000-0003-0366-0357
Funding

Funding for this research was provided by:

Bundesverband der Arzneimittel-Hersteller (n/a)
License Information

Text and Data Mining valid from 2019-06-20

Version of Record valid from 2019-06-20
More Information

Article History

Received: 29 October 2018

Accepted: 5 June 2019

First Online: 20 June 2019

Ethics approval and consent to participate

: The University of Auckland Human Participants Ethics Committee (New Zealand) provided ethics approval (020041). Written informed consent was received from each participant. The Arbeitskreis Medizinischer Ethik-Kommissionen in der Bundesrepublik Deutschland e.V. (Working Group of Medical Ethics Commissions in the Federal Republic of Germany e.V.) provided written confirmation that no additional German ethics committee approval was required for this study to be conducted in Germany (6 October 2017).

: Not applicable.

: The author has received travel and speaker funding from Bundesverband der Arzneimittel-Hersteller (BAH) a pharmaceutical industry organisation in Germany, and received funding from a pharmacy retail group, pharmaceutical companies and pharmacy organisations for reclassification consultancy and research outside of Germany.

Document is current

Any future updates will be listed below